SBIR/STTR Research Award

SILICON VULNERABLE PLAQUE SENSOR

Award identifier 7f5b73ae231492557eafc45d0f7fefeef79dcc5ffbb391897531f7b34874b5f3Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$101,361

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Photon Imaging, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

The objective of this proposal is to develop an intravascular imaging detector based on solid-state silicon sensor, to identify vulnerable coronary artery plaques. Currently, coronary angiography is unable to define the status of the atheroma and only measures the luminal dimensions of the blood vessel, without providing information about plaque content. The proposed new silicon detector will work by sensing beta particles from plaque-binding radiotracers. Thereby, a signature will be obtained for the 70% of heart attacks that are caused by minimally obstructive vulnerable plaques which are too small to be detected by angiography. This signature will enable targeted and cost effective therapies to prevent acute coronary artery diseases such as: unstable angina, acute myocardial infarction, and sudden cardiac death. In Phase I we will develop a prototype silicon sensor for detecting radiotracer emissions originating from vulnerable plaque, optimize the prototype sensor, prepare detector assemblies and characterize their performance using plaque labeling radiotracers in order to assess the feasibility of the approach for intravascular plaque detection. Preliminary studies show that for silicon the beta/gamma ratio is greatly improved over other technologies. In addition, the silicon offers other advantages such as reduced detector size for enhance clinical. In Phase II, a prototype catheter system will be fabricated and evaluated using animal models. PROPOSED COMMERCIAL APPLICATIONS: The commercial and medical value of a device that can enable preemptive treatment of coronary artery disease is self evident. Over 2 million catheterization diagnostic procedures are performed annually worldwide that would immediately quality for augmentation: with catheter based diagnosis of vulnerable plaque.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.